MOTILENT LIMITED

EC2A 2BB (London)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£263,610

Mar 23 - Mar 28

Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases

Horizon Europe Guarantee award to MOTILENT LIMITED and Alex Menys

£182,000

May 20 - Nov 20

Quantitative Reporting in Crohn’s Disease: Maximising available MRI data to better direct patient treatment, speed up treatment decisions and improve healthcare outcomes

Innovate UK award to MOTILENT LIMITED and Alex Menys

£1,574,005

Mar 20 - Mar 23

Quantitative Reporting in Crohn’s Disease: Maximising available MRI data to better direct patient treatment, speed up treatment decisions and improve healthcare outcomes

ISCF award to MOTILENT LIMITED and Alex Menys

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}